Jay H. Ryu
Mayo Clinic
Internal medicineRadiologySurgeryPathologyRetrospective cohort studyIntensive care medicineImmunologyBiopsyRespiratory diseaseUsual interstitial pneumoniaInterstitial lung diseaseLungIdiopathic pulmonary fibrosisDiseaseLung biopsyLymphangioleiomyomatosisPulmonary fibrosisMedicinePulmonary function testingGastroenterology
Publications 508
#1Gretchen A. Colbenson (Mayo Clinic)H-Index: 1
Last. Jay H. RyuH-Index: 80
view all 4 authors...
#1Takeshi JohkohH-Index: 54
#2Kyung Soo Lee (SMC: Samsung Medical Center)H-Index: 65
Last. Hiroto HatabuH-Index: 61
view all 22 authors...
Summary Increasing use of molecular targeting agents and immune checkpoint inhibitors has increased the frequency and broadened the spectrum of lung toxicity, particularly in patients with cancer. In this position paper from the Fleischner Society, the authors provide diagnostic criteria and management recommendations of drug-related pneumonitis for radiologists, clinicians, clinical trialists, and trial sponsors.
1 CitationsSource
#1Bilal F. Samhouri (Mayo Clinic)H-Index: 1
#2Yasmeen K. Tandon (Mayo Clinic)H-Index: 1
Last. Jay H. Ryu (Mayo Clinic)H-Index: 80
view all 7 authors...
Abstract Background Exogenous lipoid pneumonia (ELP) develops when lipid-containing substances enter the airways through aspiration or inhalation, and incite an inflammatory response. The diagnosis of ELP is often difficult as findings may be nonspecific. ELP’s clinical course has not been well-characterized. Research Question What are the presenting clinico-radiologic features of ELP, its causative agents, and clinical course? Study Design and Methods We searched the Mayo Clinic electronic medi...
#1Trinh T. Nguyen (Mayo Clinic)
#2Hiroshi Sekiguchi (Mayo Clinic)H-Index: 17
Last. Jay H. Ryu (Mayo Clinic)H-Index: 80
view all 4 authors...
Abstract Background Intrathoracic involvement with lymphomas is common and manifests lymphadenopathy as well as a wide spectrum of imaging abnormalities in the lungs. Intravascular large B-cell lymphoma (IVLBCL) is a rare extranodal subtype of large B-cell lymphoma that typically involves small blood vessels and is difficult to detect. Methods Using a computer-assisted search, we identified patients with histopathologically proven IVLBCL in the lungs at Mayo Clinic from 2001 through 2018. Medica...
#1Gaurav Goyal (UAB: University of Alabama at Birmingham)H-Index: 13
#2Jithma P. Abeykoon (Mayo Clinic)H-Index: 9
Last. Ronald S. Go (UMN: University of Minnesota)
view all 18 authors...
#1Pierre-Antoine Juge (University of Paris)H-Index: 7
#2Joyce S. Lee (University of Colorado Denver)H-Index: 32
Last. Philippe Dieudé (University of Paris)H-Index: 40
view all 55 authors...
QUESTION ADDRESSED BY THE STUDY Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is disputed. We aimed to evaluate the association of prior MTX use with development of RA-ILD. METHODS Through a case-control study design with discovery and international replication samples, we examined the association of MTX exposure with ILD ...
10 CitationsSource
#1Misbah Baqir (Mayo Clinic)H-Index: 8
#2Amit Vasirreddy (Berkshire Medical Center)
Last. Jay H. Ryu (Mayo Clinic)H-Index: 80
view all 7 authors...
Abstract Background It is unknown whether gastroesophageal reflux disease (GERD) is a risk factor or consequence of idiopathic pulmonary fibrosis (IPF). This study aimed to determine whether patients with IPF were more likely to have GERD compared with age- and sex-matched controls who either had 1) interstitial lung disease (ILD) other than IPF or 2) no diagnosed lung disease (population control). Methods We used the medical records-linkage system of the Rochester Epidemiology Project (REP) to ...
#1Teng Moua (Mayo Clinic)H-Index: 17
#2Aahd Kubbara (Mayo Clinic)
Last. Roberto P. Benzo (Mayo Clinic)H-Index: 26
view all 8 authors...
Patient-reported outcomes in fibrotic interstitial lung disease may be additionally predicted by novel assessments of self-management ability and affecthttps://bit.ly/3iwP5M2
#1Gretchen A. Colbenson (Mayo Clinic)H-Index: 1
#2Timothy M. Dempsey (Mayo Clinic)H-Index: 3
Last. Jay H. RyuH-Index: 80
view all 6 authors...
#1Antonious Z. Hazim (Mayo Clinic)H-Index: 1
#2Gordon Ruan (Mayo Clinic)H-Index: 3
Last. Ronald S. Go (Mayo Clinic)H-Index: 29
view all 15 authors...
Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration-approved treatments in adult LCH to establish optimal first-line therapy. We conducted a retrospective, single-center case series evaluating the use of BRAF inhibitors in adult patients with BRAFV600E - LCH proven by biopsy. Our case series is the first to report the use of BRAF inhibitors as first-line therapy in adults with LCH. We also report the efficacy with sing...
3 CitationsSource
Close Researchers